The impact of COVID-19 on patients with IBD in a prospective European cohort study.
J Crohns Colitis
; 2022 Jun 29.
Article
in English
| MEDLINE | ID: covidwho-2227464
ABSTRACT
INTRODUCTION:
There are concerns on the potential impact of the COVID-19 outbreak on patients with inflammatory bowel disease (IBD).AIM:
To report the impact of the COVID-19 outbreak in a European prospective cohort study of patients with IBD. PATIENTS ANDMETHODS:
We prospectively collected data from 5,457 patients with IBD nested in the ongoing I-CARE project and still followed up in April 2020, with monthly online monitoring of clinical activity, treatment, imaging and endoscopy. Investigators were also contacted to report incidental cases.RESULTS:
In total, 233 (4.3%) reported COVID-19 and 12 (0.2%) severe COVID-19, with no COVID-19 deaths. The risk of COVID-19 in patients with IBD was not increased compared to the general population (SIR 1.18 95%CI [1.03-1.34], p = 0.009), as well as the risk of severe COVID-19 (SIR 0.69 95%CI [0.35-1.20], p = 0.93). We did not observe any negative impact of the different IBD-related medication on the risk of either COVID-19 or severe COVID-19. In 2020, the COVID-19 outbreak resulted in a drastic decrease in endoscopic and imaging procedures from March to May 2020 compared to 2018 and 2019. No impact on clinical IBD disease activity as well as ongoing treatment were noted.CONCLUSION:
No increase in either COVID-19 or severe COVID-19 incidences were observed in patients with IBD. There was no impact of COVID-19 on IBD-related medication and clinical activity. Access to endoscopy and imaging was restricted during the first months of the first COVID-19 outbreak.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Language:
English
Journal subject:
Gastroenterology
Year:
2022
Document Type:
Article
Affiliation country:
Ecco-jcc
Similar
MEDLINE
...
LILACS
LIS